AR086984A1 - Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer - Google Patents

Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer

Info

Publication number
AR086984A1
AR086984A1 ARP120102176A ARP120102176A AR086984A1 AR 086984 A1 AR086984 A1 AR 086984A1 AR P120102176 A ARP120102176 A AR P120102176A AR P120102176 A ARP120102176 A AR P120102176A AR 086984 A1 AR086984 A1 AR 086984A1
Authority
AR
Argentina
Prior art keywords
cxcr4
cancer treatment
cxcr4 antibody
chain variable
variable domain
Prior art date
Application number
ARP120102176A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR086984A1 publication Critical patent/AR086984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente solicitud se refiere a un método para tratar el cáncer mediante la administración de un anticuerpo monoclonal anti-CXCR4 que tiene la capacidad de inducir una o más funciones efectoras.Reivindicación 1: Un anticuerpo humanizado que se une a CXCR4, o un fragmento de unión que contiene CH2 de éste; dicho anticuerpo humanizado comprende un dominio variable de la cadena pesada que se selecciona entre las secuencias SEQ ID Nº 7 a 10 y un dominio variable de la cadena ligera que se selecciona entre las secuencias SEQ ID Nº 11 a 17; para su empleo en un método del tratamiento del cáncer mediante la destrucción de una célula cancerígena que expresa CXCR4 mediante la inducción de, al menos, una función efectora, en la presencia de células efectoras o componentes del complemento.
ARP120102176A 2011-06-20 2012-06-19 Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer AR086984A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499004P 2011-06-20 2011-06-20
EP11305773 2011-06-20

Publications (1)

Publication Number Publication Date
AR086984A1 true AR086984A1 (es) 2014-02-05

Family

ID=44718440

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102176A AR086984A1 (es) 2011-06-20 2012-06-19 Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer

Country Status (13)

Country Link
US (1) US20140120555A1 (es)
EP (1) EP2721069A1 (es)
JP (1) JP6223966B2 (es)
KR (1) KR20140041698A (es)
CN (1) CN103649120A (es)
AR (1) AR086984A1 (es)
AU (1) AU2012274104B2 (es)
BR (1) BR112013032456A2 (es)
CA (1) CA2838484A1 (es)
MA (1) MA35173B1 (es)
MX (1) MX2013015061A (es)
RU (1) RU2013158624A (es)
WO (1) WO2012175576A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY190252A (en) * 2013-08-02 2022-04-08 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
MX2018003317A (es) * 2015-09-18 2018-11-09 The General Hospital Corp Dba Massacsetts General Hospital Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos.
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
EP3765519B1 (en) * 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
JP2021519298A (ja) 2018-03-27 2021-08-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 紫外線シグナルを使用した力価のリアルタイムモニタリング
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CZ294425B6 (cs) 1997-04-14 2005-01-12 Micromet Ag Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2278003B2 (en) * 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN100423777C (zh) * 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1921090B1 (en) 2005-07-22 2015-01-14 Kyowa Hakko Kirin Co., Ltd. Genetically modified antibody composition
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EA018836B1 (ru) * 2006-10-02 2013-11-29 Медарекс, Л.Л.К. Человеческие антитела, которые связываются с cxcr4, и их применение
EA201071300A1 (ru) * 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
BR112013032456A2 (pt) 2016-11-22
MX2013015061A (es) 2014-07-30
KR20140041698A (ko) 2014-04-04
JP2014525899A (ja) 2014-10-02
US20140120555A1 (en) 2014-05-01
CA2838484A1 (en) 2012-12-27
AU2012274104B2 (en) 2017-06-15
WO2012175576A1 (en) 2012-12-27
RU2013158624A (ru) 2015-07-27
EP2721069A1 (en) 2014-04-23
MA35173B1 (fr) 2014-06-02
AU2012274104A1 (en) 2014-01-09
JP6223966B2 (ja) 2017-11-01
CN103649120A (zh) 2014-03-19
NZ618655A (en) 2015-09-25

Similar Documents

Publication Publication Date Title
AR086984A1 (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR083293A1 (es) Agentes de union a cd33
ECSP17005649A (es) Anticuerpos anti-tau humanizados
BR112017003582A2 (pt) anticorpos, composições e usos
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure